Cell-cycle phase progression analysis identifies three unique phenotypes in soft tissue sarcoma.

Autor: Cullen MM; Department of Orthopaedic Surgery, Duke University Medical Center, Durham, NC, USA. mark.cullen@duke.edu., Lazarides AL; Department of Orthopaedic Surgery, Moffitt Cancer Center, Tampa, FL, USA., Pittman PD; Department of Neuropathology, Duke University Health System, Durham, NC, USA., Flamant EM; Department of Orthopaedic Surgery, University of Illinois, Chicago, IL, USA., Stoeber KL; Lucy Cavendish College, Cambridge University, Cambridge, UK.; Cancer Research UK Chromosomal Replication Group, Wolfson Institute for Biomedical Research, University College London, London, UK., Stoeber K; Department of Pathology and Cancer Institute, University College London, London, UK.; Wolfson Institute for Biomedical Research, University College London, London, UK., Visguass JD; Department of Orthopaedic Surgery, Duke University Medical Center, Durham, NC, USA.; Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA., Brigman BE; Department of Orthopaedic Surgery, Duke University Medical Center, Durham, NC, USA.; Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA., Riedel RF; Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA.; Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA.; Department of Medicine, Duke University Medical Center, Durham, NC, USA., Cardona DM; Department of Pathology, Duke University Medical Center, Durham, NC, USA., Somarelli JA; Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA.; Department of Medicine, Duke University Medical Center, Durham, NC, USA., Eward WC; Department of Orthopaedic Surgery, Duke University Medical Center, Durham, NC, USA.; Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA.
Jazyk: angličtina
Zdroj: BMC cancer [BMC Cancer] 2024 Oct 17; Vol. 24 (1), pp. 1288. Date of Electronic Publication: 2024 Oct 17.
DOI: 10.1186/s12885-024-13043-6
Abstrakt: Purpose: Loddo et al. (Br J Cancer 100:959-70, 2009) established the prognostic significance of cell cycle markers and "Cell-Cycle Phenotypes" in breast carcinoma. This study aims to 1) identify prognostic cell-cycle markers in sarcoma, and 2) assess the prognostic potential of specific cell-cycle phenotypes in sarcoma.
Methods: Tissue samples from 128 soft tissue sarcomas were stained for four cell cycle-specific markers: Mcm2, Geminin, Plk1, and H3S10ph. Only primary soft tissue tumors (liposarcoma, leiomyosarcoma, synovial sarcoma, and undifferentiated pleomorphic sarcoma) were included in the analysis. Any tumor coming from a recurrent or metastatic lesion were excluded from the analysis. Three cell-cycle phenotypes (I, II, III) were derived from marker expression patterns. Prognostic significance was evaluated in a subset of primary soft tissue sarcomas using Cox regression for survival analysis.
Results: Compared to phenotype I, the phenotype III tumors had a decreased 5-year overall survival (HR 6.81 [2.36-19.61]; p =  < 0.001), 5-year disease-free survival (HR 1.07 (1.02-1.18); p = 0.004), and 5-year metastasis-free survival (HR 4.34 [1.58-11.93]; p = 0.004). High expression of Plk1 was associated with decreased 5-year overall survival (HR: 4.04 CI [1.21-6.67; p = 0.02) and 5-year metastasis-free survival (HR: 2.91 CI [1.15-7.37]; p = 0.03). Geminin was also found to have a decreased 5-year overall survival (HR:2.84 CI [1.21-6.67]; p = 0.02). No statistical difference in prognostication were noted between phenotypes and the AJCC system.
Conclusions: We identified three unique sarcoma cell cycle phenotypes that have prognostic significance. This performs similarly to the AJCC staging system.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: